

**Systematic review and meta-analysis of randomised, placebo-controlled,
trials of non-individualised homeopathic treatment:
Study protocol**

¹Robert T Mathie

²Lynn A Legg

³Jürgen Clausen

⁴Jonathan R T Davidson

⁵Suzanne M Lloyd

⁵Ian Ford

¹ British Homeopathic Association, Luton, UK

² Department of Biomedical Engineering, University of Strathclyde, Glasgow, UK

³ Karl und Veronica Carstens-Stiftung, Essen, Germany

⁴ Department of Psychiatry and Behavioral Science, Duke University Medical Center,
Durham, North Carolina, USA

⁵ Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK

Version 1.0

30 October 2014

INTRODUCTION

Homeopathy is a system of medicine that uses specific preparations of substances whose effects, when administered to healthy subjects, correspond to the manifestations of the disorder (symptoms, clinical signs, pathological states) in the individual patient.^a It is believed that the effect is to stimulate a healing response in the patient.¹ Homeopathic medicines are also used in other therapeutic approaches such as anthroposophic medicine^b and homotoxicology.^c

There are several distinct forms of homeopathy, the main types being ‘individualised’ homeopathy, ‘clinical’ homeopathy, ‘complex’ homeopathy, and isopathy. In **individualised homeopathy** – as originally defined by its founder, Samuel Hahnemann – typically a single homeopathic medicine is selected on the basis of the ‘total symptom picture’ of a patient, including his/her mental, general and constitutional type. In **clinical homeopathy**, one or more homeopathic medicines are administered for standard clinical situations or conventional diagnoses. In **complex homeopathy**, several homeopathic medicines are combined in a fixed (‘complex’) formulation. **Isopathy** is the use of homeopathic dilutions from the causative agent of the disease itself, or from a product of the disease process, to treat the condition;¹ isopathic medicines include organisms and allergens prescribed on a basis different from individualised homeopathic prescribing in the classical sense.

A previous review protocol focused on **individualised** homeopathy.² The current protocol focuses solely on **non-individualised** homeopathy, which includes all interventions

^a The US National Center for CAM defines homeopathy as a “whole medical system” because it is “built upon a complete system of theory and practice” (<http://nccam.nih.gov/health/backgrounds/wholemed.htm>). Accessed 16 January 2013.

^b Medical approach founded by R Steiner and I Wegman integrating conventional medicine with the influence of soul and spirit on the human being.

^c Medical approach founded by HH Reckeweg based on interpreting disease as an expression of the defensive effort of the organism against pathogenic toxins and the possibility of detoxification by the application of specific homeopathic medicines.

that have involved the same, specified, homeopathic medication being allocated to each and every participant in the clinical trial: clinical homeopathy, complex homeopathy or isopathy.

The nature of the research evidence in homeopathy has long been a matter of scientific debate. Recently, however, the argument has begun to reach the point of impasse. Homeopathy’s advocates tend to deny the worth of placebo-controlled randomised controlled trials (RCTs),^{e.g. 3} whilst its critics dispute the therapy’s scientific rationale and/or the existence of any positive findings in the research literature.⁴ There is a need to temper these divergent opinions by considering the existing evidence based on a complete and objective assessment of the facts, including the nature and the quality of the research evidence, with an additional requirement to reflect the distinction between individualised and non-individualised homeopathy.

The pinnacle of the hierarchy of clinical research publications (‘type 1’ evidence) comprises systematic reviews (SRs), of which several have been published on RCTs in homeopathy. Some SRs have focused on specific medical conditions, with conclusions that are variously positive,^{e.g. 5,6,7} negative^{e.g. 8,9,10} or non-conclusive.^{e.g. 11,12,13}

Five ‘global’, or ‘comprehensive’, SRs have examined the RCT research literature on homeopathy as a whole, including the broad spectrum of medical conditions that have been researched, and by all forms of homeopathy. Four of these SRs reached the conclusion that, overall, the homeopathic intervention probably differs from placebo.^{14,15,16,17} When Linde and colleagues carried out a sensitivity analysis on the data that informed their 1997 global SR based on trial quality, the observed effects were substantially reduced, though homeopathy remained significantly more effective than placebo until all but the final 5 highest-quality trials out of 89 were excluded from the analysis.¹⁸ Neither of Linde’s reviews found sufficient evidence to draw conclusions about the ‘efficacy of homeopathy’ for any specific medical condition. The SR by Shang et al, published in 2005, concluded that there was “weak

evidence for a specific effect of homeopathic remedies... compatible with the notion that the clinical effects of homeopathy are placebo effects".¹⁹ Shang's methods and conclusions have subsequently been criticised.²⁰

One other global SR considered solely RCTs that were controlled by an intervention other than placebo (OTP).²¹

Previous reviews contain two key limitations:

1. Global SRs have typically assessed the RCT findings of all forms of homeopathy (individualised, clinical, complex, isopathy) together, as if they are the same intervention. As discussed above, there are marked differences in the nature of the therapeutic interventions, and the distinction between them is important, for it affects the interpretation of the research findings in each case. Placebo-controlled RCTs of a particular homeopathic medicine (non-individualised homeopathy) allows conclusions about that medicine's efficacy for the clinical condition investigated in the cohort of subjects concerned; in a similarly controlled trial of individualised homeopathy, however, such 'efficacy' applies to the range of homeopathic medicines prescribed to the individuals included in the trial. Moreover, in studies of individualised homeopathy, 'efficacy' is potentially masked by a significant effect of the in-depth homeopathic consultation that is common to the test group and the control group.^{22,23}

2. Though not *systematic* reviews, some accounts of homeopathy research, including our own,²⁴ have summarised the findings of RCTs using 'vote counting', whereby each trial is designated 'positive' or 'negative' or 'non-conclusive' based on its most important statistical findings. While such an approach has the advantage that it overcomes problems associated with heterogeneous groups of trials and reflects the condition-specific nature of the research evidence, it does not grapple with the key matter of magnitude of treatment effect. Nor does this method reflect a single 'main outcome measure' of each trial in a systematic way. There is a need to quantify treatment effects of homeopathic interventions for given medical conditions, and the use of a systematically and consistently determined

'main outcome measure' per RCT would be helpful in focusing on matters of greatest clinical importance.

Four additional matters also need to be addressed:

a. Nearly all SRs to date have examined RCTs of treatment and of prophylaxis indistinguishably. It is not clear, however, whether the homeopathic rationale for each approach is the same: an individual person's symptoms are the target of homeopathic treatment but other rationales, including *anticipated* symptoms, provide the basis for homeopathic prophylaxis.

b. The internal validity of a trial (the extent to which the design, conduct and analysis has minimised or avoided biases in its comparison of treatments^{25,26}) reflects the quality of its methods of randomisation, blinding, and a number of other key attributes. Some comprehensive reviews have used a numerical system such as the Jadad score²⁷ to assess RCT quality in homeopathy. More modern systems of assessment, such as that adopted by Shang et al,¹⁹ do not allocate single overall scores; instead, they adopt qualitative standards against which a trial's internal validity is judged as having low, uncertain or high risk of bias.²⁸ Neither system is intended to enable the identification of finer distinctions in degree of quality.

c. Concerns about research quality in homeopathy go beyond its internal validity.²⁹ Previous SRs of homeopathy have failed to assess the quality of the homeopathic intervention itself (i.e. the model validity³⁰ of the original RCT). Without such additional assessment, conclusions about trial quality in homeopathy are severely limited. We have devised a method to assess the model validity of clinical trials of homeopathic treatment.³¹

d. Few of the previous SRs in homeopathy have made the distinction between substantive and minor research articles or between the peer-reviewed and non-peer-reviewed research literature: a research dissertation or an abstract presented at a conference, for example, has usually been given a status equal to that of a paper published in a high-ranking academic journal.^{e.g. 16,19} Peer review is an important, though by no means flawless, surrogate for

research quality: for some, it is “an essential arbiter of scientific quality” and “information about the status of research results is as important as the findings themselves”.³² SRs in homeopathy need to reflect, *a priori*, the distinction between the substantive peer-reviewed journal literature and other, lesser, categories of research evidence.

Aim of the study

The aim of this SR/meta-analysis is to examine the efficacy of the homeopathic medicines that have been used in the context of placebo-controlled trials of non-individualised homeopathic treatment. We include RCTs of adults and/or children, and for each medical condition that has been the subject of such research. A single ‘main outcome measure’ is identified per RCT.

Reflecting matters of study quality (including internal validity and model validity), the present study will focus on the two key issues outlined above: (1) in a global meta-analysis, to ascertain if non-individualised homeopathic treatment can be distinguished from the same form of treatment but using placebo medicines; (2) in condition-specific meta-analyses, to quantify any effect of non-individualised homeopathic treatment for medical conditions in which there is >1 eligible placebo-controlled RCT.

METHODS

Eligibility criteria, information sources, study selection and data collection

The eligible research literature has been identified, to PRISMA standards, in a previous paper by our group.³³ From 489 potentially eligible records found up to and including December 2011, 263 fulfilled the criteria of a substantive, non-repeat, journal paper that reported a randomised and controlled study of homeopathy.

Ninety-six of those records reported a placebo-controlled RCT of non-individualised homeopathic treatment and were published in the peer-reviewed journal literature. **Figure 1** is based on our original PRISMA flowchart,³³ in which specific **exclusion criteria** have been applied, as appropriate, to the 96 records:

- Trials of homeopathic prophylaxis^d
- Trials with crossover design^e
- Research using radionically prepared ‘homeopathic’ medicines³⁴
- The tested intervention is homeopathy combined with other (complementary or conventional) medicine or therapy. (This study design is distinct from that in which concomitant conventional medication remains ongoing in the subjects of each study group)
- Placebo-controlled trial explicitly designated “single-blinded” (i.e. patient-blinded)
- Other specified reason.

Twenty-nine records met those exclusion criteria, leaving 67 that are eligible for SR/meta-analysis – see Figure 1.

All 67 records in this final group will be included in the formal SR, together with relevant records identified in a supplementary search of the literature up to the end of 2013. Any record whose main outcome measurement is not extractable (see below) will be ineligible for meta-analysis.

Only published data will be eligible for analysis. Because it is recognised that contacting the original authors of RCTs may lead to overly positive answers,²⁸ the authors of eligible papers will not be approached for clarification on unclear or missing facets of any of their methods or results; however, original authors’ cross-reference to their previously published study methods will be followed up and taken into account as necessary. For trials with more than two study groups, only the data concerning comparisons

^d *Prophylaxis*: A trial on healthy individuals in which the homeopathic intervention aims to prevent the occurrence of disease *de novo* (i.e. ‘primary prevention’). Studies using a strategy of primary prevention, with subsequent treatment as necessary, are categorised ‘treatment’ trials. *Treatment*: A trial in which the first homeopathic intervention takes places after the onset of active symptoms associated with disease. Studies on sub-clinical disease or the control of recurrent disease (‘secondary prevention’) are categorised ‘treatment’ trials. RCTs of homeopathic prophylaxis will be appraised in a separate SR.

^e In due course, crossover trials will be appraised separately from those of parallel-group design.

between non-individualised homeopathy and placebo will be extracted from the 67 papers.

Study characteristics and data items

Two reviewers independently will extract relevant data using a standard data recording approach, in spreadsheet format (Microsoft *Excel*). The data extracted per trial will include, as appropriate: demographics of participants (gender, age range, medical condition); study setting; potency or potencies of homeopathic medicines; whether a pilot trial; ‘main outcome measure’ (see below) and measured end-point; other outcome measures reported; funding source/s. The statistical items noted will be: whether power calculation carried out; whether intention-to-treat (ITT) analysis; sample size and missing data for each intervention group.

Identification of ‘main outcome measure’ per RCT:

For each trial, and for the purposes of risk-of-bias assessment, we shall identify a single ‘main outcome measure’ using a refinement of the approaches adopted by Linde et al. and by Shang et al.^{16,19} Each trial’s ‘main outcome measure’ will be identified based on the following hierarchical ranking order (consistent with the WHO ICF Classification System for Levels of Functioning Linked to Health Condition):^f

- Mortality
- Morbidity
 - Treatment failure
 - Pathology; symptoms of disease
- Health impairment (loss/abnormality of function, incl. presence of pain)
- Limitation of activity (disability, incl. days off work/school because of ill health)
- Restriction of participation (quality of life)
- Surrogate outcome (e.g. blood test data, bone mineral density).

We shall follow the WHO ICF system regardless of what measure may have been identified by the investigators as their ‘primary outcome’. In cases where, in the judgment of

^f Towards a Common Language for Functioning, Disability and Health. ICF: The International Classification of Functioning, Disability and Health. Geneva; World Health Organization, 2002.

the reviewers, there are two or more outcome measures of equal greatest importance within the WHO ICF rank order, the designated ‘main outcome measure’ will be selected randomly from those two or more options using the toss of coins or dice.

Unless otherwise indicated, the single end-point (measured from the start of the intervention) associated with the designated ‘main outcome measure’ will be taken as the last follow-up at which data are reported for that outcome.

Risk of bias in individual studies

Using the standard criteria defined by Cochrane,²⁸ the extraction of information will enable appraisal of ‘low risk’, ‘uncertain risk’ or ‘high risk’ of bias with respect to: (Domain I) the methods used to generate the random sequence; (Domain II) the method of allocation concealment used to implement the random sequence; (Domain IIIa) the blinding of participants and study personnel; (Domain IIIb) the blinding of outcome assessors;^g (Domain IV) whether all the randomised patients are accounted for in the analysis; (Domain V) whether there is evidence of selective outcome reporting; (Domain VI) whether there is evidence of other bias.

Two assessors will mutually scrutinise and compare their judgments, with discrepancies between them resolved by consensus discussion. A risk-of-bias summary table will be produced, characterising each of the 67 eligible records. For Domain IV, a trial will automatically be regarded as no better than ‘unclear’ if there is greater than 20% participant attrition rate, irrespective of whether ITT analysis has been carried out. Domain V will automatically be designated ‘high risk of balance’ if its main outcome measure cannot be extracted to enable calculation of ‘treatment effect’ (see below). Assessment of Domain VI will explicitly include appraisal of data imbalance at baseline; the source of any research sponsorship will be taken into account for subgroup analysis (see below), not in risk-of-bias assessment *per se*.

^g Domains are designated IIIa and IIIb to reflect their common focus on matters connected with blinding.

Rating of trials for risk of bias (internal validity):

By the standard Cochrane approach, each trial is designated: **low risk of bias** for all key domains; **uncertain risk of bias** for one or more key domains; **high risk of bias** for one or more key domains.²⁸ This three-tiered rating style will be insufficient to enable meaningful sensitivity analysis of trial quality in meta-analysis (see also below). We therefore propose to adopt a novel method of nomenclature, based on the Cochrane approach, for rating risk-of-bias characteristics across all domains per trial:

A = Low risk of bias in all seven domains.

B_x = Uncertain risk of bias in *x* domains; low risk of bias in all other domains.

C_{y.x} = High risk of bias in *y* domains; uncertain risk of bias in *x* domains; low risk of bias in all other domains.

This approach yields a total of 36 sub-tiers of risk of bias (see **Table 1**).

We designate a ‘B1’-rated trial *reliable evidence* if the sole uncertainty in its risk of bias was for one of domains IV, V or VI (i.e. it was required to be judged free of bias for each of domains I, II, IIIA and IIIB).

Assessment of model validity

We shall assess the model validity of eligible RCTs using our criterion-based method of appraisal,³¹ and which harmonises both with the Cochrane risk-of-bias approach and our quality rating system. The primary model validity findings will be published separately from the paper that reports risk-of-bias assessment and meta-analysis.

Summary measures for ‘main outcome’

A ‘summary of findings’ table (containing relevant raw data from the trials) and a summary risk-of-bias table will be prepared.

For the 67 records of non-individualised homeopathy, we shall examine: (1) **overall treatment effect**; (2) **disease-specific treatment effects**. In both these categories, ‘treatment effect’ will be taken as the difference between the homeopathy and the

placebo groups at our pre-determined end-point of the trial:

- For **dichotomous measures**: odds ratio (OR), with 95% CI;^h
- For **continuous measures**: standardised mean difference (SMD), calculated using the inverse variance method, with 95% CI.

In trials where the main outcome measure is a continuous variable, and where there are insufficient data presented to identify the mean and/or the SD per group at the defined end-point, the necessary data will be calculated or estimated, if possible, by imputing relevant other data (e.g. SD at baseline) from the same study.³⁵

If the original paper does not provide or inform adequate data on the selected ‘main outcome measure’ to enable extraction or calculation of mean and/or SD, we shall describe the selected main outcome as ‘not estimable’: an alternative, estimable, outcome will **not** be sought.

Consistent with the above, the following studies will be excluded from meta-analysis:

- Those that present non-parametric data only, and where there is no information that enables the data distribution to be assessed;
- Those from which the necessary data cannot be extracted (not provided or uninterpretable).

Synthesis of results

1) Overall ‘treatment effect’ of non-individualised homeopathy

The ‘main outcome’ data will be synthesised for meta-analysis in two separate sets of studies as appropriate: (1) using the odds ratio (OR) of each trial; (2) using the SMD of each trial.³⁶ A summary measure of ‘treatment effect’ will be identified across all included studies for each of those two sets. The ‘random effects’ statistical model will be used rather than the ‘fixed effects’ model.³⁷

^h If the main outcome is reported as data in more than two categories, these will be dichotomised as appropriate.

Illustration of findings will be by means of forest plot.

Data from the two sets of studies will then also be combined into a single forest plot, re-expressing SMDs by transformation to OR, using an approximation method proposed by Chinn³⁸ and recommended by Cochrane.³⁶

2) *Disease-specific treatment effect of non-individualised homeopathy*

For each specific medical condition for which there is >1 RCT with extractable main outcome, the data will be synthesised using meta-analysis methods. For each of these particular analyses, a **single** ‘main outcome measure’ will be designated, if possible, for each medical condition, and reflecting the WHO classification ranking approach (see above). A summary estimate of treatment effect per condition, with 95% CI and *P* value, will be illustrated by means of forest plot. The ‘random effects’ statistical model will again be used.³⁶

3) *Measures of consistency:*

Asymmetry of each of the above forest plots will be determined from visual inspection of the associated funnel plot graph and by interpretation of the asymmetry (heterogeneity) statistic, I^2 .

Risk of bias, and other assessments of quality, across studies

An assessment of the overall quality of the evidence (based on the GRADE approach³⁵) will take into consideration, with equal weight, the evaluations of risk of bias and of model validity across the range of RCTs concerned.

The ratings obtained for risk of bias and for model validity (see Table 1) may also be used to ascertain the degree of **correlation** between them (Spearman’s rank correlation coefficient).

This across-study facet of the review work will be the subject of a separate paper from the two that report, respectively, the SR/meta-analysis results and the primary model validity assessments.

Additional analyses on overall ‘treatment effect’ of non-individualised homeopathy (specified prior to data analysis)

Sensitivity analyses:

We shall carry out sensitivity analysis by the trials’ risk-of-bias ratings, and reflecting the extent of *reliable evidence*.


The sensitivity analysis will address the question: “Do the conclusions of the excluded (lower-quality) papers complement or contradict the results from the meta-analysis?”

Sub-group analyses:

Comparative forest plots are planned as follows:

- Whether or not the study is included in previous comprehensive SR/meta-analysis of homeopathy RCTs;^{16,19}
- Pilot (or ‘preliminary’ or feasibility’) study, as defined by the original authors;
- Sample size;
- Potency/potencies of homeopathic medicines used.
- Whether or not the data for meta-analysis have been imputed;
- Whether or not the research sponsor is an organisation (e.g. homeopathic pharmacy) that potentially has vested interest in the trial findings.
- Whether the medical condition studied is ‘acute’ or ‘chronic’ (prior duration of symptoms, ≤ 3 months).

FIGURE 1: Details of numbered references as per original PRISMA flowchart³³



References for Figure 1:

- A42 Aabel S (2001). Prophylactic and acute treatment with the homeopathic medicine *Betula 30c* for birch pollen allergy: a double-blind, randomized, placebo-controlled study of consistency of VAS responses. *British Homeopathic Journal*; **90**:73–78.
- A43 Aabel S, Laerum E, Dølvik S, Djupesland P (2000). Is homeopathic 'immunotherapy' effective? A double-blind, placebo-controlled trial with the isopathic remedy *Betula 30c* for patients with birch pollen allergy. *British Homeopathic Journal*; **89**:161–168.
- A44 Aabel S (2000). No beneficial effect of isopathic prophylactic treatment for birch pollen allergy during a low-pollen season: a double-blind, placebo-controlled clinical trial of homeopathic *Betula 30c*. *British Homeopathic Journal*; **89**:169–173.
- A45 Adkison JD, Bauer DW, Chang T (2010). The effect of topical arnica on muscle pain. *Annals of Pharmacotherapy*; **44**:1579-1584.
- A46 Baillargeon L, Drouin J, Desjardins L, Leroux D, Audet D (1993). Les effets de l'*Arnica Montana* sur la coagulation sanguine. Essai clinique randomisé [The effects of *Arnica Montana* on blood coagulation. Randomized controlled trial]. *Canadian Family Physician*; **39**:2362-2367.
- A47 Baker DG, Myers SP, Howden I, Brooks L (2003). The effects of homeopathic *Argentum nitricum* on test anxiety. *Complementary Therapies in Medicine*; **11**:65–71.
- A48 Balzarini A, Felisi E, Martini A, De Conno F (2000). Efficacy of homeopathic treatment of skin reactions during radiotherapy for breast cancer: a randomized, double-blind clinical trial. *British Homeopathic Journal*; **89**:8–12.
- A49 Beer AM, Heiliger F (1999). *Caulophyllum D4* zur Geburtsinduktion bei vorzeitigem Blasensprung - eine Doppelblindstudie [Randomized, double-blind trial of *Caulophyllum D4* for induction of labour after premature rupture of the membranes at term]. *Geburtshilfe und Frauenheilkunde*; **59**:431–435.
- A50 Belon P, Banerjee P, Choudhury SC, Banerjee A, Biswas SJ, Karmakar SR, Pathak S, Guha B, Chatterjee S, Bhattacharjee N, Das JK, Khuda-Bukhsh AR (2006). Can administration of potentized homeopathic remedy, *Arsenicum album*, alter antinuclear antibody (ANA) titre in people living in high-risk arsenic contaminated areas? I. A correlation with certain hematological parameters. *Evidence-Based Complementary and Alternative Medicine*; **3**:99-107.
- A51 Belon P, Banerjee A, Karmakar SR, Biswas SJ, Choudhury SC, Banerjee P, Das JK, Pathak S, Guha B, Paul S, Bhattacharjee N, Khuda-Bukhsh AR (2007). Homeopathic remedy for arsenic toxicity? Evidence-based findings from a randomized placebo-controlled double blind human trial. *Science of the Total Environment*; **384**:141-50.
- A52 Bergmann J, Luft B, Boehmann S, Runnebaum B, Gerhard I (2000). Die Wirksamkeit des Komplexmittels *Phyto-Hypophyson® L* bei weiblicher, hormonell bedingter Sterilität. Eine randomisierte, plazebokontrollierte, klinische Doppelblindstudie [The efficacy of the complex medication *Phyto-Hypophyson L* in female, hormone-related sterility. A randomized, placebo-controlled clinical double-blind study]. *Forschende Komplementärmedizin und Klassische Naturheilkunde*; **7**:190–199.
- A53 Bernstein S, Donsky H, Gulliver W, Hamilton D, Nobel S, Norman R (2006). Treatment of mild to moderate psoriasis with *Reliéva*, a *Mahonia aquifolium* extract - a double-blind, placebo-controlled study. *American Journal of Therapeutics*; **13**:121-126.
- A54 Bernstein JA, Davis BP, Picard JK, Cooper JP, Zheng S, Levin LS (2011). A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis. *Annals of Allergy, Asthma and Immunology*; **107**: 171-178.
- A55 Berrebi A, Parant O, Ferval F, Thene M, Ayoubi JM, Connan L, Belon P (2001). Traitement de la douleur de la montée laiteuse non souhaitée par homéopathie dans le postpartum immédiat [Treatment of pain due to unwanted lactation with a homeopathic preparation given in the immediate post-partum period]. *Journal de gynécologie, obstétrique et biologie de la reproduction*; **30**:353–357.
- A56 Bignamini M, Bertoli A, Consolandi AM, Dovera N, Saruggia M, Taino S, Tubertini A (1987). Controlled double-blind trial with *Baryta carbonica 15CH* versus placebo in a group of hypertensive subjects confined to bed in two old people's homes. *British Homoeopathic Journal*; **76**:114–119.
- A57 Brinkhaus B, Wilkens JM, Lüdtke R, Hunger J, Witt CM, Willich SN (2006). Homeopathic arnica therapy in patients receiving knee surgery: results of three randomised double-blind trials. *Complementary Therapies in Medicine*; **14**:237–246.
- A58 Brydak LB, Denys A (1999). The evaluation of humoral response and the clinical evaluation of a risk-group patients' state of health after administration of the homeopathic preparation *Gripp-Heel* during the influenza epidemic season 1993/94. *International Review of Allergology and Clinical Immunology*; **5**:223–227.

- A59 Cialdella P, Boissel JP, Belon P (2001). Spécialités homéopathiques en substitution de benzodiazépines: étude en double-insu vs. placebo [Complex homeopathic medicines as substitutes for benzodiazepines: double-blind study vs. placebo]. *Thérapie*; **56**:397–402.
- A60 Clark J, Percivall A (2000). A preliminary investigation into the effectiveness of the homeopathic remedy, *Ruta graveolens*, in the treatment of pain in plantar fasciitis. *British Journal of Podiatry*; **3**:81–85.
- A61 Cornu C, Joseph P, Gaillard S, Bauer C, Vedrinne C, Bissery A, Melot G, Bossard N, Belon P, Lehot J-J (2010). No effect of a homeopathic combination of *Arnica montana* and *Bryonia alba* on bleeding, inflammation, and ischaemia after aortic valve surgery. *British Journal of Clinical Pharmacology*; **69**:136–142.
- A62 Diefenbach M, Schilken J, Steiner G, Becker HJ (1997). Homöopathische Therapie bei Erkrankungen der Atemwege. Auswertung einer klinischen Studie bei 258 Patienten [Homeopathic therapy in respiratory tract diseases. Evaluation of a clinical study in 258 patients]. *Zeitschrift für Allgemeinmedizin*; **73**:308–314.
- A63 Ernst E, Saradeth T, Resch KL (1990). Complementary therapy of varicose veins – a randomized, placebo-controlled, double-blind trial. *Phlebology*; **5**:157–163.
- A64 Ferley JP, Zmirou D, D'Adhemar D, Balducci F (1989). A controlled evaluation of a homeopathic preparation in the treatment of influenza like syndromes. *British Journal of Clinical Pharmacology*; **27**:329–335.
- A65 Ferrara P, Marrone G, Emmanuele V, Nicoletti A, Mastrangelo A, Tiberi E, Ruggiero A, Fasano A, Paolini Paoletti F (2008). Homotoxicological remedies versus desmopressin versus placebo in the treatment of enuresis: a randomised, double-blind, controlled trial. *Pediatric Nephrology*; **23**:269–74. Epub 2007 Feb 20.
- A66 Fisher P, Greenwood A, Huskisson EC, Turner B, Belon P (1989). Effect of homeopathic treatment on fibrositis (primary fibromyalgia). *British Medical Journal*; **299**: 365–366.
- A67 Frass M, Dielacher C, Linkesch M, Endler C, Muchitsch I, Schuster E, Kaye A (2005). Influence of potassium dichromate on tracheal secretions in critically ill patients. *Chest*; **127**:936–941.
- A68 Freitas LAS, Goldenstein E, Sanna OM (1995). A relação médico-paciente indireta e o tratamento homeopático na asma infantil [The indirect patient-doctor relationship and the homeopathic treatment of childhood asthma]. *Revista de Homeopatia*; **60**:26–31.
- A69 Friese K-H, Zabalotnyi DI (2007). Homöopathie bei akuter Rhinosinusitis. Eine doppelblinde, placebokontrollierte Studie belegt die Wirksamkeit und Verträglichkeit eines homöopathischen Kombinations-arzneimittels [Homeopathy in acute rhinosinusitis. A double-blind, placebo controlled study shows the efficiency and tolerability of a homeopathic combination remedy]. *HNO*; **55**:271–277.
- A70 Friese K-H, Feuchter U, Möller H (1997). Die homöopathische Behandlung von adenoiden Vegetationen [Homeopathic treatment of adenoid vegetations. Results of a prospective, randomized double-blind study]. *HNO*; **45**:618–624.
- A71 Furuta SE, Weckx LLM, Figueiredo CR (2003). Estudo clínico, randomizado, duplocego, em crianças com adenóide obstrutiva, submetidas a tratamento homeopático [Prospective, randomized, double-blind clinical trial about efficacy of homeopathic treatment in children with obstructive adenoid]. *Revista Brasileira de Otorrinolaringologia*; **69**: 343-347.
- A72 Furuta SE, Weckx LLM, Figueiredo CR (2007). Tratamento Homeopático da amigdalite recorrente em crianças: um estudo randomizado controlado [Homeopathic treatment of recurrent tonsillitis in children: a randomized controlled trial]. *Revista de Homeopatia*; **70**:21-26.
- A73 Garrett B, Harrison PV, Stewart T, Porter I (1997). A trial of homeopathic treatment of leg ulcers. *Journal of Dermatological Treatment*; **8**:115–117.
- A74 Gerhard I, Pateck A, Monga B, Blank A, Gorkow C (1998). Mastodynon bei weiblicher Sterilität. Randomisierte, plazenbokontrollierte, klinische doppelblindstudie. [Mastodynon for female infertility. Randomised, placebo controlled, clinical double-blind study]. *Forschende Komplementärmedizin*; **5**:272-278.
- A75 GRECHO (Groupe de Recherches et d'Essais Cliniques en Homéopathie), U292 INSERM, ARC (Association de Recherche en Chirurgie), GREPA (Groupe de Recherche et d'Étude de la Paroi Abdominal) (1989). Evaluation de deux produits homéopathiques sur la reprise du transit après chirurgie digestive - Un essai contrôlé multicentrique [Evaluation of the effects of two homeopathic preparations on the resumption of intestinal peristalsis after digestive tract surgery – A multicentre controlled trial]. *Presse Médicale*; **18**:59-62.
- A76 Hart O, Mullee MA, Lewith G, Miller J (1997). Double-blind, placebo-controlled, randomized clinical trial of homeopathic *arnica C30* for pain and infection after total abdominal hysterectomy. *Journal of the Royal Society of Medicine*; **90**:73–78.
- A77 Heusser P, Berger S, Stutz M, Hüsler A, Haerberli A, Wolf U (2009). Efficacy of homeopathically potentized antimony on blood coagulation. A randomized placebo controlled crossover trial. *Forschende Komplementärmedizin*; **16**:14–18.

- A78 Hitzenger G, Rehak PH (2005). Zur Wirkung eines homöopathi-schen Fertigarzneimittels auf den Blutdruck von Hypertonikern: Eine randomisierte doppelblinde kontrollierte Parallelgruppen-Vergleichsstudie [The effect of a homeopathic drug on the blood pressure of hypertensive patients: a randomized double-blind, controlled, parallel-group, comparative trial]. *Wiener Medizinische Wochenschrift*; **155**:392–396.
- A79 Hofmeyr GJ, Piccioni V, Blauhof P (1990). Postpartum homeopathic Arnica montana: a potency-finding pilot study. *British Journal of Clinical Practice*; **44**:619–621.
- A80 Jacobs J, Guthrie BL, Montes GA, Jacobs LE, Mickey-Colman N, Wilson AR, DiGiacomo R (2006). Homeopathic combination remedy in the treatment of acute childhood diarrhea in Honduras. *Journal of Alternative and Complementary Medicine*; **12**:723–732.
- A81 Jacobs J, Fernandez EA, Merizalde B, Avila-Montes GA, Crothers D (2007). The use of homeopathic combination remedy for dengue fever symptoms: a pilot RCT in Honduras. *Homeopathy*; **96**:22–26.
- A82 Jawara N, Lewith G, Mullee M, Smith C (1997). Homeopathic Arnica and Rhus Toxicodendron for delayed onset muscle soreness: a randomized, double-blind, placebo-controlled trial. *British Homeopathic Journal*, **86**:10–15.
- A83 Kaziro GS (1984). Metronidazole (Flagyl) and Arnica montana in the prevention of post-surgical complications, a comparative placebo controlled clinical trial. *British Journal of Oral & Maxillofacial Surgery*; **22**:42–49.
- A84 Khuda-Bukhsh AR, Pathak S, Guha B, Karmakar SR, Das JK, Banerjee P, Biswas SJ, Mukherjee P, Bhattacharjee N, Choudhury SC, Banerjee A, Bhadra S, Mallick P, Chakrabarti J, Mandal B (2005). Can homeopathic arsenic remedy combat arsenic poisoning in humans exposed to groundwater arsenic contamination? A preliminary report on first human trial. *Evidence-Based Complementary and Alternative Medicine*; **2**:537-548.
- A85 Khuda-Bukhsh AR, Banerjee A, Biswas SJ, Karmakar SR, Banerjee P, Pathak S, Guha B, Haque S, Das D, De A, Das D, Boujedaini N (2011a). An initial report on the efficacy of a millesimal potency Arsenicum Album LM 0/3 in ameliorating arsenic toxicity in humans living in a high-risk arsenic village. *Journal of Chinese Integrative Medicine / Zhong Xi Yi Jie He Xue Bao*; **9**: 596-604.
- A86 Kim LS, Riedlinger JE, Baldwin CM, Hilli L, Khalsa SV, Messer SA, Waters RF (2005). Treatment of seasonal allergic rhinitis using homeopathic preparation of common allergens in the southwest region of the US: a randomized, controlled clinical trial. *Annals of Pharmacotherapy*; **39**:617–624.
- A87 Kneis KC, Gandjour A (2009). Economic evaluation of Sinfrontal® in the treatment of acute maxillary sinusitis in adults. *Applied Health Economics and Health Policy*; **7**: 181-191.
- A88 Kolia-Adam N, Solomon E, Bond J, Deroukakis M (2008). The efficacy of Coffea cruda on insomnia: a double blind trial. *Simillimum*; **21**: 91-99.
- A89 Kotlus BS, Heringer DM, Dryden RM (2010). Evaluation of homeopathic arnica montana for ecchymosis after upper blepharoplasty: A placebo-controlled, randomized, double-blind study. *Ophthalmic Plastic and Reconstructive Surgery*; **26**:395-397.
- A90 La Pine MP, Malcomson FN, Torrance JM, Marsh NV (2006). Night shift: can a homeopathic remedy alleviate shift lag? *Dimensions of Critical Care Nursing*; **25**:130–136.
- A91 Labrecque M, Audet D, Latulippe LG, Drouin J (1992). Homeopathic treatment of plantar warts. *Canadian Medical Association Journal*; **146**:1749–1753.
- A92 Leaman AM, Gorman D (1989). Cantharis in the early treatment of minor burns. *Archives of Emergency Medicine*; **6**:259–261.
- A93 Lewith G, Watkins AD, Hyland ME (2002). Use of ultramolecular potencies of allergen to treat asthmatic people allergic to house dust mite: double blind randomized controlled clinical trial. *British Medical Journal*; **324**:520–523.
- A94 Lipman D, Sexton G, Schlessler J (1999). A randomized double-blind placebo-controlled evaluation of the safety and efficacy of a natural over-the-counter (OTC) medication in the management of snoring. *Sleep and Breathing*; **3**: 53-56.
- A95 McCutcheon LE (1996). Treatment of anxiety with a homeopathic remedy. *Journal of Applied Nutrition*; **48**:2–6.
- A96 Meissner K, Ziep D (2011). Organ-specificity of placebo effects on blood pressure. *Autonomic Neuroscience*, **164**: 62-66.
- A97 Merklinger S, Messemer C, Niederle S (1995). Ekzembhandlung mit cardiospermum halicacabum: Cardiospermum-Salbe und Salbengrundlage im Halbseitenvergleich - eine kontrollierte Studie [Treatment of eczema with Cardiospermum halicacabum: Cardiospermum ointment and the ointment vehicle - a controlled study]. *Zeitschrift für Phytotherapie*; **16**: 263-266.
- A98 Mokkaipatti R (1992). An experimental double-blind study to evaluate the use of Euphrasia in preventing conjunctivitis. *British Homeopathic Journal*; **81**:22–24.

- A99 Mousavi F, Sherafati S, Mojaver YN (2009). Ignatia in the treatment of oral lichen planus. *Homeopathy*; **98**: 40-44.
- A100 Oberbaum M, Yaniv I, Ben-Gal Y, Stein J, Ben-Zvi N, Freedman LS, Branski D (2001). A randomized, controlled clinical trial of the homeopathic medication Traumeel S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. *Cancer*; **92**:684–690.
- A101 Oberbaum M, Galoyan N, Lerner-Geva L, Singer SR, Grisaru S, Shashar D, Samueloff A (2005). The effect of the homeopathic remedies Arnica and Bellis perennis on mild postpartum bleeding – a randomized, double-blind, placebo-controlled study – preliminary results. *Complementary Therapies in Medicine*; **13**:87–90.
- A102 Pach D, Brinkhaus B, Roll S, Wegscheider K, Icke K, Willich SN, Witt CM (2011). Efficacy of injections with *Disci/Rhus toxicodendron compositum* for chronic low back pain - A randomized placebo-controlled trial. *PLoS One*; **6**: e26166. Epub 2011 Nov 8.
- A103 Padilha RQ, Riera R, Atallah AN (2011). Homeopathic *Plumbum metallicum* for lead poisoning: a randomized clinical trial. *Homeopathy*. 2011 Jul;100(3):116-121.
- A104 Papp R, Schuback G, Beck E, Burkard G, Bengel J, Lehl S, Belon P (1998). Oscilloccinum® in patients with influenza-like syndromes: a placebo-controlled double-blind evaluation. *British Homoeopathic Journal*; **87**:69–76.
- A105 Paris A, Gonnet N, Chaussard C, Belon P, Rocourt F, Saragaglia D, Cracowski JL (2008). Effect of homeopathy on analgesic intake following knee ligament reconstruction: a phase III monocentre randomized placebo controlled study. *British Journal of Clinical Pharmacology*; **65**:180–187.
- A106 Paris A, Schmidlin S, Mouret S, Hodaj E, Marijnen P, Boujedaini N, Polosan M, Cracowski JL (2011). Effect of Gelsemium 5CH and 15CH on anticipatory anxiety: A phase III, single-centre, randomized, placebo-controlled study. *Fundamental and Clinical Pharmacology*; **25**:42.
- A107 Plezbert JA, Burke JR (2005). Effects of the homeopathic remedy Arnica on attenuating symptoms of exercise-induced muscle soreness. *Journal of Chiropractic Medicine*; **4**: 152-161.
- A108 Rahlfs VW, Mössinger P (1976). Zur Behandlung des Colon irritabile: Ein multizentrischer plazebo-kontrollierter Doppelblindversuch in der Allgemeinen Praxis [Treatment of irritable colon: A multicenter placebo-controlled double-blind study in general practice]. *Arzneimittel Forschung*; **26**:2230–2234.
- A109 Rahlfs VW, Mössinger P (1978). Asa foetida bei Colon irritabile – Doppelblindversuch [Asa foetida in the treatment of the irritable colon – a double-blind trial]. *Deutsche medizinische Wochenschrift*; **104**:140–143.
- A110 Ramelet AA, Buchheim G, Lorenz P, Imfeld M (2000). Homeopathic Arnica in postoperative haematomas: a double-blind study. *Dermatology*; **201**: 347-348.
- A111 Reilly DT, Taylor MA, McSharry C, Aitchison T (1986). Is homeopathy a placebo response? Controlled trial of homeopathic potency, with pollen in hayfever as model. *Lancet*; ii:881–885.
- A112 Reilly D, Taylor MA, Beattie NGM, Campbell JH, McSharry C, Aitchison TC, Carter R, Stevenson RD (1994). Is evidence for homeopathy reproducible? *Lancet*; **344**:1601–1606.
- A113 Robertson A, Suryanarayanan R, Banerjee A (2007). Homeopathic Arnica montana for post tonsillectomy analgesia: a randomised placebo control trial. *Homeopathy*; **96**:17–21.
- A114 Saruggia M, Corghi E (1992). Effects of homoeopathic dilutions of china rubra on intradialytic symptomatology in patients treated with chronic haemodialysis. *British Homoeopathic Journal*; **81**:86-88.
- A115 Schirmer K-P, Fritz M, Jäckel WH (2000). Wirksamkeit von Formica rufa und Eigenblut-Injektionen bei Patienten mit ankylosierender Spondylitis: eine doppelblinde, randomisierte Studie [Efficacy of Formica rufa and reinjection of patient's own blood on patients with ankylosing spondylitis: a double-blind, randomized study]. *Zeitschrift für Rheumatologie*; **59**:321-329.
- A116 Schmidt JM, Ostermayr B (2002). Does a homeopathic ultramolecular dilution of Thyroidinum 30cH affect the rate of body weight reduction in fasting patients? A randomized placebo-controlled double-blind clinical trial. *Homeopathy*; **91**:197–206.
- A117 Seeley BM, Denton AB, Ahn MS, Maas CS (2006). Effect of homeopathic Arnica montana on bruising in face-lifts: results of a randomized, double-blind, placebo-controlled clinical trial. *Archives of Facial Plastic Surgery*; **8**:54–59.
- A118 Shipley M, Berry H, Broster G, Jenkins M, Clover A, Williams I (1983). Controlled trial of homoeopathic treatment of osteoarthritis. *Lancet*; i:97–98.
- A119 Simpson JJ, Donaldson I, Davies WE (1998). Use of homeopathy in the treatment of tinnitus. *British Journal of Audiology*; **32**:227–233.
- A120 Singer SR, Amit-Kohn M, Weiss S, Rosenblum J, Maoz G, Samuels N, Lukasiewicz E, Freedman L, Paltiel O, Itzhaki M, Niska M, Oberbaum M (2010). Traumeel S for pain relief following hallux valgus surgery: a randomized controlled trial. *BMC Clinical Pharmacology*; **10**: 9.

- A121 Smith SA, Baker AE, Williams JH (2002). Effective treatment of seborrhoeic dermatitis using a low dose, oral homeopathic medication consisting of potassium bromide, sodium bromide, nickel sulfate, and sodium chloride in a double-blind, placebo-controlled study. *Alternative Medicine Review*; **7**:59–67.
- A122 Stevinson C, Devaraj VS, Fountain-Barber A, Hawkins S, Ernst E (2003). Homeopathic arnica for prevention of pain and bruising: randomized placebo-controlled trial in hand surgery. *Journal of the Royal Society of Medicine*; **96**:60–65.
- A123 Taylor MA, Reilly D, Llewellyn-Jones RH, McSharry C, Aitchison TC (2000). Randomised controlled trial of homeopathy versus placebo in perennial allergic rhinitis with overview of four trial series. *British Medical Journal*; **321**:471–476.
- A124 Tuten C, McLung J (1999). Reducing muscle soreness with Arnica montana. *Alternative and Complementary Therapies*; **5**:369-372.
- A125 Tveiten D, Bruseth S, Borchgrevink CF, Løhne K (1991). Effekt av Arnica D 30 ved hard fysisk anstrengelse. En dobbeltblind randomisert undersøkelse under Oslo maraton 1990 [Effect of Arnica D30 on hard physical exertion. A double-blind randomized trial during the 1990 Oslo Marathon]. *Tidsskrift for den Norske Laegeforening*, **111**:3630–3631.
- A126 Tveiten D, Bruseth S, Borchgrevink CF, Norseth J (1998). Effects of the homeopathic remedy Arnica D30 on marathon runners: a randomized, double-blind study during the 1995 Oslo Marathon. *Complementary Therapies in Medicine*, **6**:71–74.
- A127 Vickers AJ, Fisher P, Smith C, Wyllie SE, Lewith GT (1997). Homeopathy for delayed onset muscle soreness: a randomized double blind placebo controlled trial. *British Journal of Sports Medicine*, **31**:304–307.
- A128 Vickers AJ, Fisher P, Smith C, Wyllie SE, Rees R (1998). Homeopathic Arnica 30X is ineffective for muscle soreness after long-distance running: a randomized, double-blind, placebo-controlled trial. *Clinical Journal of Pain*, **14**:227–231.
- A129 von Hagens C, Schiller P, Godbillon B, Osburg J, Klose C, Limplrecht R, Strowitzki T (2011). Treating menopausal symptoms with a complex remedy or placebo: a randomized controlled trial. *Climacteric*: Epub ahead of print.
- A130 Weiser M, Clasen B (1994). Randomisierte plazebokontrollierte Doppelblindstudie zur Untersuchung der klinische Wirksamkeit der homöopathischen Euphorbium compositum-Nasentropfen S bei chronischer Sinusitis [Randomized, placebo-controlled, double-blind study of the clinical efficacy of the homeopathic Euphorbium compositum-S nasal spray in cases of chronic sinusitis]. *Forschende Komplementärmedizin*; **1**:251–259.
- A131 Wiesenauer M, Gaus W (1985). Double-blind trial comparing the effectiveness of the homeopathic preparation Galphimia potentization D6, Galphimia dilution 10⁻⁶ and placebo on pollinosis. *Arzneimittel Forschung*; **35**:1745–1747.
- A132 Wiesenauer M, Gaus W, Bohnacker U, Häussler S (1989). Wirksamkeitsprüfung von homöopathische Kombinationspräparaten bei Sinusitis. Ergebnisse einer randomisierten Doppelblindstudie unter Praxisbedingungen [Efficiency of homeopathic preparation combinations in sinusitis. Results of a randomized double blind study with general practitioners]. *Arzneimittel Forschung*; **39**:620-625.
- A133 Wiesenauer M, Gaus W, Häussler S (1990). Behandlung der Pollinosis mit Galphimia glauca. Eine Doppelblindstudie unter Praxisbedingungen [Treatment of pollinosis with the homeopathic preparation Galphimia glauca. A double-blind trial in clinical practice]. *Allergologie*; **13**:359–363.
- A134 Wiesenauer M, Gaus W (1991). Wirksamkeitsnachweis eines Homöopathikums bei chronischer Polyarthrit. Eine randomisierte Doppelblindstudie bei nieder-gelassenen Ärzten [A randomized double-blind trial on the efficacy of a homeopathic drug for rheumatoid arthritis]. *Aktuelle Rheumatologie*; **16**:1–21.
- A135 Wiesenauer M, Lüdtke R (1995). The treatment of pollinosis with Galphimia glauca D4 - a randomized placebo-controlled double-blind clinical trial. *Phytomedicine*; **2**: 3-6.
- A136 Wolf M, Tamaschke C, Mayer W, Heger M (2003). Wirksamkeit von Arnica bei Varizenoperation: Ergebnisse einer randomisierten, doppelblinden, Placebo-kontrollierten Pilot-Studie [Efficacy of Arnica in varicose vein surgery: results of a randomized, double-blind, placebo-controlled pilot study]. *Forschende Komplementärmedizin und Klassische Naturheilkunde*; **10**:242–247.
- A137 Zabolotnyi DI, Kneis KC, Richardson A, Rettenberger R, Heger M, Kaszkin-Bettag M, Heger PW (2007). Efficacy of a complex homeopathic medication (Sinfrontal) in patients with acute maxillary sinusitis: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial. *Explore (NY)*; **3**:98–109.

TABLE 1: *Extended Cochrane rating for Risk of Bias (RoB)*

A: Low RoB for all domains;

B: Uncertain RoB for designated number of domains;

C: High RoB for designated number of domains; uncertain RoB for designated number of domains.

- 1) **A:** ‘Low RoB’ in all 7 domains
- 2) **B1:** ‘Uncertain RoB’ in any 1 domain, ‘Low RoB’ in others
- 3) **B2:** ‘Uncertain RoB’ in any 2 domains, ‘Low RoB’ in others
- 4) **B3:** ‘Uncertain RoB’ in any 3 domains, ‘Low RoB’ in others
- 5) **B4:** ‘Uncertain RoB’ in any 4 domains, ‘Low RoB’ in others
- 6) **B5:** ‘Uncertain RoB’ in any 5 domains, ‘Low RoB’ in others
- 7) **B6:** ‘Uncertain RoB’ in any 6 domains, ‘Low RoB’ in other
- 8) **B7:** ‘Uncertain RoB’ in all 7 domains

- 9) **C1.0:** ‘High RoB’ in any 1 domain, ‘Low RoB’ in all others
- 10) **C1.1:** ‘High RoB’ in any 1 domain, ‘Uncertain RoB’ in any 1 domain, ‘Low RoB’ in others
- 11) **C1.2:** ‘High RoB’ in any 1 domain, ‘Uncertain RoB’ in any 2 domains, ‘Low RoB’ in others
- 12) **C1.3:** ‘High RoB’ in any 1 domain, ‘Uncertain RoB’ in any 3 domains, ‘Low RoB’ in others
- 13) **C1.4:** ‘High RoB’ in any 1 domain, ‘Uncertain RoB’ in any 4 domains, ‘Low RoB’ in others
- 14) **C1.5:** ‘High RoB’ 1 domain, ‘Uncertain RoB’ in any 5 domains, ‘Low RoB’ in other
- 15) **C1.6:** ‘High RoB’ 1 domain, ‘Uncertain RoB’ in all 6 others

- 16) **C2.0:** ‘High RoB’ in any 2 domains, ‘Low RoB’ in all others
- 17) **C2.1:** ‘High RoB’ in any 2 domains, ‘Uncertain RoB’ in any 1 domain, ‘Low RoB’ in others
- 18) **C2.2:** ‘High RoB’ in any 2 domains, ‘Uncertain RoB’ in any 2 domains, ‘Low RoB’ in others
- 19) **C2.3:** ‘High RoB’ in any 2 domains, ‘Uncertain RoB’ in any 3 domains, ‘Low RoB’ in others
- 20) **C2.4:** ‘High RoB’ in any 2 domains, ‘Uncertain RoB’ in any 4 domains, ‘Low RoB’ in other
- 21) **C2.5:** ‘High RoB’ in any 2 domains, ‘Uncertain RoB’ in all 5 others

- 22) **C3.0:** ‘High RoB’ in any 3 domains, ‘Low RoB’ in all others
- 23) **C3.1:** ‘High RoB’ in any 3 domains, ‘Uncertain RoB’ in any 1 domain, ‘Low RoB’ in others
- 24) **C3.2:** ‘High RoB’ in any 3 domains, ‘Uncertain RoB’ in any 2 domains, ‘Low RoB’ in others
- 25) **C3.3:** ‘High RoB’ in any 3 domains, ‘Uncertain RoB’ in any 3 domains, ‘Low RoB’ in other
- 26) **C3.4:** ‘High RoB’ in any 3 domains, ‘Uncertain RoB’ in all 4 others

- 27) **C4.0:** ‘High RoB’ in any 4 domains, ‘Low RoB’ in all others
- 28) **C4.1:** ‘High RoB’ in any 4 domains, ‘Uncertain RoB’ in any 1 domain, ‘Low RoB’ in others
- 29) **C4.2:** ‘High RoB’ in any 4 domains, ‘Uncertain RoB’ in any 2 domains, ‘Low RoB’ in other
- 30) **C4.3:** ‘High RoB’ in any 4 domains, ‘Uncertain RoB’ in all 3 others

- 31) **C5.0:** ‘High RoB’ in any 5 domains, ‘Low RoB’ in both others
- 32) **C5.1:** ‘High RoB’ in any 5 domains, ‘Uncertain RoB’ in any 1 domain, ‘Low RoB’ in other
- 33) **C5.2:** ‘High RoB’ in any 5 domains, ‘Uncertain RoB’ in both others

- 34) **C6.0:** ‘High RoB’ in any 6 domains, ‘Low RoB’ in other
- 35) **C6.1:** ‘High RoB’ in any 6 domains, ‘Uncertain RoB’ in other

- 36) **C7.0:** ‘High RoB’ in all 7 domains.

REFERENCES

- ¹ Swayne, J (2000). *International Dictionary of Homeopathy*, Churchill Livingstone, Edinburgh.
- ² Mathie RT, Legg LA, Clausen J, Davidson JRT, Lloyd SM, Ford I. Systematic review and meta-analysis of randomised, placebo-controlled, trials of individualised homeopathic treatment: Study protocol. Version 1.0; 25 January 2013. http://www.britishhomeopathic.org/wp-content/uploads/2013/05/Study_protocol_for_systematic_review.pdf
- ³ Vithoulkas G (2011). Another point of view for the homeopathic trials and meta-analyses. <http://www.vithoulkas.com/en/research/articles/2247.html> [Accessed 16.01.13].
- ⁴ Sense About Science (2006). Homeopathy. <http://www.senseaboutscience.org/data/files/resources/54/Homeopathy.pdf> [Accessed 16.01.13].
- ⁵ Jacobs J, Jonas WB, Jimenez-Perez M, Crothers D (2003). Homeopathy for childhood diarrhea: combined results and metaanalysis from three randomized, controlled clinical trials. *Pediatric Infectious Disease Journal*; **22**: 229–234.
- ⁶ Taylor MA, Reilly D, Llewellyn-Jones RH, McSharry C, Aitchison TC (2000). Randomised controlled trials of homoeopathy versus placebo in perennial allergic rhinitis with overview of four trial series. *British Medical Journal*; **321**: 471–476.
- ⁷ Schneider B, Klein P, Weiser M (2005). Treatment of vertigo with a homeopathic complex remedy compared with usual treatments: a meta-analysis of clinical trials. *Arzneimittelforschung*; **55**: 23–29.
- ⁸ Ernst E, Barnes J (1998). Are homoeopathic remedies effective for delayed-onset muscle soreness? – A systematic review of Placebo-controlled trials. *Perfusion (Nürnberg)*; **11**: 4–8.
- ⁹ Ernst E (1999). Homeopathic prophylaxis of headaches and migraine? A systematic review. *Journal of Pain and Symptom Management*; **18**: 353–357.
- ¹⁰ Ernst E (2011b). Homeopathy for insomnia and sleep-related disorders: A systematic review of randomised controlled trials. *Focus on Alternative and Complementary Therapies*; **16**: 195–199.
- ¹¹ Smith CA (2004). Homoeopathy for induction of labour. *Cochrane Database of Systematic Reviews*: CD003399.
- ¹² Mathie RT, Frye J, Fisher P (2012). Homeopathic Oscillococtinum[®] for preventing and treating influenza and influenza-like illness. *Cochrane Database of Systematic Reviews*; Issue 12: Article number CD001957.
- ¹³ Long L, Ernst E (2001). Homeopathic remedies for the treatment of osteoarthritis: a systematic review. *British Homeopathic Journal*; **90**: 37–43.
- ¹⁴ Kleijnen J, Knipschild P, ter Riet G (1991). Clinical trials of homoeopathy. *British Medical Journal*; **302**: 316–323.
- ¹⁵ Boissel JP, Cucherat M, Haugh M, Gauthier E (1996). Critical literature review on the effectiveness of homoeopathy: overview of data from homoeopathic medicine trials. In: Homoeopathic Medicine Research Group, Report of the Commission of the European Communities, Directorate-General XII – Science, Research and Development, Directorate E – RTD Actions: Life Sciences and Technologies – Medical Research. Brussels, Belgium.

-
- ¹⁶ Linde K, Clausius N, Ramirez G, Melchart D, Eitel F, Hedges LV, Jonas WB (1997). Are the clinical effects of homeopathy placebo effects? A meta-analysis of placebo-controlled trials. *Lancet*; **350**: 834–843.
- ¹⁷ Cucherat M, Haugh MC, Gooch M, Boissel JP (2000). Evidence of clinical efficacy of homeopathy – A meta-analysis of clinical trials. *European Journal of Clinical Pharmacology*; **56**: 27–33.
- ¹⁸ Linde K, Scholz M, Ramirez G, Clausius N, Melchart D, Jonas WB (1999). Impact of study quality on outcome in placebo-controlled trials of homeopathy. *Journal of Clinical Epidemiology*; **52**: 631–636.
- ¹⁹ Shang A, Huwiler-Muntener K, Nartey L, Juntherapiesi P, Dorig S, Sterne JA, Pewsner D, Egger M (2005). Are the clinical effects of homeopathy placebo effects? Comparative study of placebo-controlled trials of homeopathy and allopathy. *Lancet*; **366**: 726–732.
- ²⁰ Lüdtkke R, Rutten ALB (2008). The conclusions on the effectiveness of homeopathy highly depend on the set of analyzed trials. *Journal of Clinical Epidemiology*; **61**: 1197–1204.
- ²¹ Ernst E (1999). Classical homeopathy versus conventional treatments: a systematic review. *Perfusion (Nürnberg)*; **12**: 13–15.
- ²² Weatherley-Jones E, Thompson EA, Thomas KJ (2004). The placebo-controlled trial as a test of complementary and alternative medicine: observations from research experience of individualised homeopathic treatment. *Homeopathy*; **93**: 186–189.
- ²³ Brien S, Lachance L, Prescott P, McDermott C, Lewith G (2011). Homeopathy has clinical benefits in rheumatoid arthritis patients that are attributable to the consultation process but not the homeopathic remedy: a randomized controlled clinical trial. *Rheumatology (Oxford)*; **50**: 1070–1082.
- ²⁴ Mathie RT (2003). The research evidence base for homeopathy: a fresh assessment of the literature. *Homeopathy*; **92**: 84–91.
- ²⁵ Akobeng AK (2008). Assessing the validity of clinical trials. *Journal of Pediatric Gastroenterology and Nutrition*; **47**: 277–282.
- ²⁶ Jüni P, Altman DG, Egger M (2001). Assessing the quality of controlled clinical trials. *British Medical Journal*; **323**: 42–46.
- ²⁷ Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996). Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Controlled Clinical Trials*; **17**: 1–12.
- ²⁸ Higgins JPT, Altman DG (2011). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (eds). *Cochrane Handbook for Systematic Reviews of Interventions; Version 5.1.0*. The Cochrane Collaboration.
- ²⁹ Bell IR (2003). Evidence-based homeopathy: Empirical questions and methodological considerations for homeopathic clinical research. *American Journal of Homeopathic Medicine*; **96**: 17–31.
- ³⁰ Bornhöft G, Maxion-Bergemann S, Wolf U, Kienle GS, Michalsen A, Vollmar HC, Gilbertson S, Matthiessen PF (2006). Checklist for the qualitative evaluation of clinical studies with particular focus on external validity and model validity. *BMC Medical Research Methodology*; **6**: 56.

-
- ³¹ Mathie RT, Roniger H, Van Wassenhoven M, Frye J, Jacobs J, Oberbaum M, Bordet M-F, Nayak C, Chaufferin G, Ives JA, Dantas F, Fisher P (2012). Method for appraising model validity of randomised controlled trials of homeopathic treatment: multi-rater concordance study. *BMC Medical Research Methodology*; **12**: 49.
- ³² Sense about Science (2013). Peer review. <http://www.senseaboutscience.org/pages/peer-review.html> [accessed 17.01.13].
- ³³ Mathie RT, Hacke D, Clausen J, Nicolai T, Riley DS, Fisher P (2013). Randomised controlled trials of homeopathy in humans: characterising the research journal literature for systematic review. *Homeopathy*; **102**: 3–24.
- ³⁴ Baker DG, Myers SP, Howden I, Brooks L (2003). The effects of homeopathic *Argentum nitricum* on test anxiety. *Complementary Therapies in Medicine*; **11**: 65–71.
- ³⁵ Higgins JPT, Deeks JJ, Altman DG (2011). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (eds). *Cochrane Handbook for Systematic Reviews of Interventions; Version 5.1.0*. The Cochrane Collaboration.
- ³⁶ Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH (2011). Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (eds). *Cochrane Handbook for Systematic Reviews of Interventions; Version 5.1.0*. The Cochrane Collaboration.
- ³⁷ Deeks JJ, Higgins JPT, Altman DG (2011). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (eds). *Cochrane Handbook for Systematic Reviews of Interventions; Version 5.1.0*. The Cochrane Collaboration.
- ³⁸ Chinn S (2000). A simple method for converting an odds ratio to effect size for use in meta-analysis. *Statistics in Medicine*; **19**: 3127–3131.